In Good Health: The Alzheimer’s Research Revolution
Summary
Host Nyla Boodoo interviews New York Times reporter Pam Belluck and Dr. Jason Karlawish about recent advances in Alzheimer’s and dementia care. They discuss new FDA-approved drugs targeting amyloid, emerging tau therapies, and the distinction between dementia types like Lewy body and LATE. The experts also cover risk factors, including cardiovascular health and environmental impacts, while addressing prevention strategies and the evolving landscape of federal research funding.
Topics discussed
Introduction and sponsor messages
Guest introductions and medical disclaimer
Defining dementia, Alzheimer's, and cognitive impairment
Rising dementia rates and declining incidence per capita
Cardiovascular health links to dementia risk
Listener questions on risk assessment and caregiving
Sponsor messages and podcast promotions
Demographic disparities and genetic risk factors (APOE4)
New FDA-approved drugs: Lecanemab and Donanemab
Future of prevention and early intervention trials
Treatments for moderate to severe dementia stages
The potential for biomarker-guided prevention
Reasons for diagnosis and lifestyle interventions
Tau protein therapies and combination treatments
Environmental risks: Pollution and extreme heat
Differentiating dementia types: Vascular and Lewy Body
LATE: A new form of dementia linked to TDP-43
Frontotemporal dementia (FTD) and its challenges
Prevention strategies: Heart health, sleep, and hearing
Impact of political changes on NIH research funding
Conclusion: Hope for the future of dementia care
Listen ad-free on Castria